New Product Introduction Newsletter :Trophoblast cell-surface antigen 2 (Trop 2) and AMACR(Alpha-Methylacyl-CoA racemase)

Research tools for monoclonal rabbit antibodies

Background

Trophoblast cell-surface antigen 2 (Trop 2) is a transmembrane glycoprotein, also known as membrane component chromosome 1 surface marker 1 (M1S1), gastrointestinal antigen 733-1 (GA733-1), or epithelial glycoprotein-1 (EGP-1) in sequential discoveries. Overexpression of Trop 2 usually leads to poor prognosis in various solid tumors.Therefore, Trop 2 is considered an potential prognostic marker as well as a therapeutic target for the treatment of specific types of tumors. Moreover, in April 2020, the first Trop 2 targeting drug ‘sacituzumab govitecan’, which is an anti-Trop 2 antibody-drug conjugates, was approved in the US for the treatment of metastatic triple-negative breast cancer (TNBC).

AMACR(Alpha-Methylacyl-CoA racemase) is a peroxisomal and mitochondrial enzyme which plays critical role in the metabolism of cholesterol and branched-chain fatty acids. The function of AMACR in cancer is associated with lipid metabolism. And the activity of nuclear receptors such as farnesoid X receptor and peroxisome proliferation activation receptor is also related to AMACR. It is also relevant to the expression of cyclooxygenase-2 .

AMACR has been proved as a prostate cancer marker, and its expression is also high in other cancers such as colon cancer, liver cancer, and renal cancer. It draws a lot of attention in recent cancer research for its potential as a target of anti-cancer drugs.